Dydrogesterone (Dydrogesteronum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

"Estrogens, gestagens, their homologues and antagonists"

Included in the formulation
  • Duphaston®
    pills inwards 
    Abbott Helskea Products BV     Netherlands
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    ONLS

    АТХ:

    G.03.D.B.01   Dydrogesterone

    Pharmacodynamics:

    Synthetic analog of progesterone. Selectively binds to the endometrial progesterone receptors, penetrates into the nucleus and stimulates DNA. As a result, the synthesis of ribonucleic acids is enhanced. Accelerates the transition of the mucous membrane of the uterus from the proliferation phase to the phase of secretion. Promotes the successful implantation of a fertilized egg. Reduces contractility of the myometrium and musculature of the fallopian tubes. Promotes the development of the end ducts of the mammary glands.

    In the menopause period, the effect of estrogens on the lipid composition of the blood plasma remains without affecting the blood coagulation system. Does not affect the process of ovulation, prevents hyperplastic processes of the endometrium, including due to excessive estrogenic effects.

    Pharmacokinetics:

    After oral administration, up to 98% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 2 hours. The connection with plasma proteins is 97%.

    Metabolism in the liver by hydroxylation.

    The half-life is 7-14 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of dysfunctional uterine bleeding, premenstrual tension syndrome, dysmenorrhea, infertility, endometriosis, with the threat of abortion. Used as part of complex therapy for secondary amenorrhea. It is used for the purpose of hormone replacement therapy to neutralize the proliferation of the endometrium under the influence of estrogens.

    ICD-10

    XV.O20-O29.O20.0   Threatening abortion

    XIV.N80-N98.N97   Female infertility

    XIV.N80-N98.N96   Habitual miscarriage

    XIV.N80-N98.N95.3   Conditions associated with artificially induced menopause

    XIV.N80-N98.N95.1   Menopause and menopause in women

    XIV.N80-N98.N94.5   Secondary dysmenorrhea

    XIV.N80-N98.N94.4   Primary dysmenorrhea

    XIV.N80-N98.N94.3   Premenstrual tension syndrome

    XIV.N80-N98.N93   Other abnormal bleeding from the uterus and vagina

    XIV.N80-N98.N92   Abundant, frequent and irregular menstruation

    XIV.N80-N98.N91   Absence of menstruation, meager and rare menstruation

    XIV.N80-N98.N80   Endometriosis

    IV.E20-E35.E28   Dysfunction of the ovaries

    XIV.N80-N98.N80.9   Endometriosis, unspecified

    XIV.N80-N98.N95.8   Other specified disorders of the menopausal and perimenopausal period

    XV.O00-O08.O05   Other types of abortion

    XIV.N80-N98.N92.1   Abundant and frequent menstruation with an irregular cycle

    Contraindications:

    Hepatic insufficiency, thrombophilia, breast and genital cancers, age under 18, individual intolerance.

    Carefully:

    Arterial hypertension, chronic renal failure, epilepsy, bronchial asthma, migraine, ectopic pregnancy, hyperlipoproteinemia, lactation period, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used during pregnancy, not recommended during lactation.

    Dosing and Administration:

    Inside. It is used according to the individual scheme. The recommended frequency of reception is 2-3 times a day, 5-10 mg each.

    The highest daily dose: 30 mg.

    The highest single dose: 10 mg.

    Side effects:

    Central and peripheral nervous system: headache, migraine.

    Digestive system: rarely - cholestatic hepatitis.

    Reproductive system: "breakthrough" bleeding, increased sensitivity of mammary glands.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Phenobarbital, rifampicin and other inducers of microsomal liver enzymes weaken the effect due to the acceleration of the biotransformation of dydrogesterone.

    Special instructions:

    When "breakthrough" bleeding occurs during treatment, it is recommended to increase the dose of the drug.

    When treating the threat of interruption, the drug is effective until the eight-week gestation period.

    Instructions
    Up